Brief: Cynata Therapeutics Says US FDA Clears Ind For Co's Phase 2 Clinical Trial Of Cyp-001 In Gvhd
26/05/2022 02:24
May 26 (Reuters) - Cynata Therapeutics Ltd CYP.AX :
* US FDA CLEARS IND FOR CO'S PHASE 2 CLINICAL TRIAL OF
CYP-001 IN
GVHD
Source text for Eikon: ID:nASX2FNbZw
Further company coverage: CYP.AX
Recent news on Cynata Therapeutics
See all newsBrief: Cynata Therapeutics Says Firm Commitments Received To Raise Further A$550,000 Via Placement
Brief: Cynata Therapeutics Enters Consultancy Agreement With LIR Bio Advisory
Brief: Cynata Therapeutics Establishes Share Sale Facility For Unmarketable Parcel Holders
Brief: Cynata Therapeutics Terminates Of At-The-Market Subscription Deed
Brief: Cynata Therapeutics Posts FY2026 Loss From Ordinary Activities After Tax A$9.1 Million